Review the sources used below for this article: This article references information from the KFF (Kaiser Family Foundation) Poll: 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford This article references information from the FDA: FDA Approves First Treatment to Reduce Risk of Serious Heart Problems, Specifically in Adults with Obesity or Overweight This article references information from a recent study published in The New England Journal of Medicine : Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity This article references information from the American College of Cardiology: OASIS 4: Significant Weight Loss With Oral Semaglutide Comparable With High-Dose, SC Versions This article references information from Reuters: Lilly will have supply of new weight loss pill for many countries, exec says

If you also use insulin or sulfonylureas, your doctor may need to adjust those doses to lower the risk of hypoglycaemia
Written by Reem Al Karim & Reviewed by Paul Holmes
Community members who manage fatigue well tend to prioritize: Calorie-dense protein sources: Nuts, nut butters, full-fat Greek yogurt, salmon, eggs with yolks
A standard weight-management titration reference (based on FDA-approved Wegovy protocol): Weeks 14: 0.25 mg once weekly Weeks 58: 0.5 mg once weekly Weeks 912: 1.0 mg once weekly Weeks 1316: 1.7 mg once weekly Week 17 onward: 2.4 mg once weekly (maintenance for obesity) For T2DM glycemic control, lower maintenance doses (0.52.0 mg weekly) are used per Ozempic labeling
Some patients may come across other formats such as oral capsules, nasal sprays, or topical products online